Lexaria Bioscience Corp (LEXX)

$0.70 -0.08 (-10.04%)
Market Cap 20.13M
Revenue (ttm) 710,000.00
Net Income (ttm) -11.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,676.06%
Debt to Equity Ratio 0.00
Volume 191,828
Avg Vol 736,220
Day's Range N/A - N/A
Shares Out 24.89M
Stochastic %K 89%
Beta 0.63
Analysts Strong Sell
Price Target $4.50

Company Profile

Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. Its DehydraTECH is...

Industry: Biotechnology
Sector: Healthcare
Phone: 250 765 6424
Address:
740 McCurdy Road, Suite 100, Kelowna, Canada
hovian
hovian Jan. 15 at 7:40 PM
$LEXX tday no reason for dump... just manipulation to get some cheap shares... who ever sell, will miss the train.
0 · Reply
Boston7452
Boston7452 Jan. 15 at 7:32 PM
$LEXX 2025 commercialization strategy is more definitive than 2024 showing more confidence in their plan and suggesting they have potential partner(s) for #2 & #3.
0 · Reply
hovian
hovian Jan. 15 at 7:10 PM
$LEXX who ever is buying all my respect... what a chance u have...
0 · Reply
Boston7452
Boston7452 Jan. 15 at 6:24 PM
$LEXX "Potential to develop and launch a patented DehydraTECH-CBD product within and/or outside of the diabetes/weight loss and hypertension marketplaces"
1 · Reply
Shubeedoo
Shubeedoo Jan. 15 at 5:45 PM
$LEXX Stock is at 70 cents. Anybody hear about any paid marketing plans? Needs it bad!
1 · Reply
Boston7452
Boston7452 Jan. 15 at 5:18 PM
$LEXX All share offer at 2 wouldnt be transformative. Also if they have their own or even a co-developed patented DHT-CBD "drug" then this becomes a billion dollar company. "our quest to deliver exciting and transformative returns to all Lexaria stakeholders!"
1 · Reply
hovian
hovian Jan. 15 at 5:10 PM
$LEXX will now an all share offer make sens at $2? Maybe SP is artificially down bcz an all share offer will b made and they will use average of 60 last days as reference? I hope some big foot buy this company...
0 · Reply
Boston7452
Boston7452 Jan. 15 at 5:04 PM
$LEXX This year the hope is a licensing deal but Im skeptical it'll happen this year based on CEO's letter. Outside of that management is supposed to release their plans for the year. That could reveal something.
0 · Reply
LongLEXX
LongLEXX Jan. 15 at 4:58 PM
$LEXX Let's play "Where's the Shares"
0 · Reply
TheRealStockRocket
TheRealStockRocket Jan. 15 at 4:51 PM
$LEXX $LEXX There is so much bs and lies posted here to try to get shareholders to sell so the scalpers and swingers can load again...dont be f-ing stupid....The dd I posted is the truth straight from the company filings...do your on dd. I just keep on accumulating here...on my way to 100K shares.
0 · Reply
Latest News on LEXX
Lexaria Releases Annual Letter from the CEO

Jan 12, 2026, 9:10 AM EST - 3 days ago

Lexaria Releases Annual Letter from the CEO

Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4

Dec 30, 2025, 9:20 AM EST - 16 days ago

Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4

Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus

Dec 23, 2025, 12:06 PM EST - 23 days ago

Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus

NVO

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Dec 23, 2025, 9:29 AM EST - 23 days ago

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 16, 2025, 4:00 PM EST - 4 weeks ago

Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 15, 2025, 8:00 AM EST - 4 weeks ago

Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Nov 12, 2025, 9:10 AM EST - 2 months ago

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Lexaria Bioscience Corp. Provides Strategic Update

Oct 9, 2025, 9:20 AM EDT - 3 months ago

Lexaria Bioscience Corp. Provides Strategic Update

Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Sep 29, 2025, 4:30 PM EDT - 3 months ago

Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Sep 26, 2025, 8:10 AM EDT - 3 months ago

Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain

Sep 19, 2025, 11:20 AM EDT - 4 months ago

Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain

Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference

Aug 27, 2025, 9:20 AM EDT - 5 months ago

Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference

Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone

Aug 14, 2025, 9:20 AM EDT - 5 months ago

Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone

GLP-1 "Arms Race" Broadens to Include Dozens of Companies

Aug 6, 2025, 9:20 AM EDT - 5 months ago

GLP-1 "Arms Race" Broadens to Include Dozens of Companies

Lexaria Provides Positive Interim Results on Partial 8-week Data From Phase 1b, GLP-1-H24-4 Study

Jul 28, 2025, 9:25 AM EDT - 6 months ago

Lexaria Provides Positive Interim Results on Partial 8-week Data From Phase 1b, GLP-1-H24-4 Study

Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study

Jul 28, 2025, 9:25 AM EDT - 6 months ago

Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study

Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry

Jul 23, 2025, 9:25 AM EDT - 6 months ago

Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry

Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide

Jun 23, 2025, 9:15 AM EDT - 7 months ago

Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide

Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule

Jun 11, 2025, 9:05 AM EDT - 7 months ago

Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule

Lexaria Attending BIO International Convention

Jun 5, 2025, 9:20 AM EDT - 8 months ago

Lexaria Attending BIO International Convention

Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company

May 12, 2025, 9:00 AM EDT - 8 months ago

Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company

Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock

Apr 28, 2025, 4:15 PM EDT - 9 months ago

Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock

Lexaria Announces $2 Million Registered Direct Offering of Common Stock

Apr 25, 2025, 8:00 AM EDT - 9 months ago

Lexaria Announces $2 Million Registered Direct Offering of Common Stock

Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology

Apr 23, 2025, 9:10 AM EDT - 9 months ago

Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology

Lexaria Updates its Ongoing Human Study GLP-1-H24-4

Apr 3, 2025, 9:10 AM EDT - 10 months ago

Lexaria Updates its Ongoing Human Study GLP-1-H24-4

Lexaria's Human GLP-1 Study #5 Begins Dosing

Apr 2, 2025, 9:05 AM EDT - 10 months ago

Lexaria's Human GLP-1 Study #5 Begins Dosing

Lexarias' DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound

Mar 18, 2025, 9:15 AM EDT - 10 months ago

Lexarias' DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound

Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound(R)

Mar 18, 2025, 9:15 AM EDT - 10 months ago

Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound(R)

The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience

Feb 27, 2025, 8:00 AM EST - 11 months ago

The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience

Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm

Feb 24, 2025, 8:00 AM EST - 11 months ago

Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm

Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide

Feb 20, 2025, 8:00 AM EST - 11 months ago

Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide

Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy

Feb 11, 2025, 8:00 AM EST - 1 year ago

Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy

Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway

Feb 6, 2025, 9:40 AM EST - 1 year ago

Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway

Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval

Jan 15, 2025, 9:20 AM EST - 1 year ago

Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval

Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)

Jan 14, 2025, 9:10 AM EST - 1 year ago

Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)

Lexaria's Registered GLP-1 Study #4 Begins Dosing

Dec 19, 2024, 9:05 AM EST - 1 year ago

Lexaria's Registered GLP-1 Study #4 Begins Dosing

Lexaria Forms New Scientific Advisory Board

Dec 18, 2024, 9:25 AM EST - 1 year ago

Lexaria Forms New Scientific Advisory Board

Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience

Dec 17, 2024, 9:10 AM EST - 1 year ago

Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience

Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5

Dec 9, 2024, 9:10 AM EST - 1 year ago

Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5

Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs

Nov 26, 2024, 9:20 AM EST - 1 year ago

Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs

Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled

Nov 25, 2024, 9:00 AM EST - 1 year ago

Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled

ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study

Nov 20, 2024, 9:05 AM EST - 1 year ago

ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study

Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study

Nov 14, 2024, 9:10 AM EST - 1 year ago

Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study

Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss

Nov 13, 2024, 9:20 AM EST - 1 year ago

Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss

Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments

Nov 7, 2024, 9:15 AM EST - 1 year ago

Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments

Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study

Oct 24, 2024, 9:10 AM EDT - 1 year ago

Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study

Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study

Oct 22, 2024, 9:20 AM EDT - 1 year ago

Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study

Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Oct 16, 2024, 4:00 PM EDT - 1 year ago

Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Oct 15, 2024, 8:25 AM EDT - 1 year ago

Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing

Oct 9, 2024, 9:05 AM EDT - 1 year ago

Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing

hovian
hovian Jan. 15 at 7:40 PM
$LEXX tday no reason for dump... just manipulation to get some cheap shares... who ever sell, will miss the train.
0 · Reply
Boston7452
Boston7452 Jan. 15 at 7:32 PM
$LEXX 2025 commercialization strategy is more definitive than 2024 showing more confidence in their plan and suggesting they have potential partner(s) for #2 & #3.
0 · Reply
hovian
hovian Jan. 15 at 7:10 PM
$LEXX who ever is buying all my respect... what a chance u have...
0 · Reply
Boston7452
Boston7452 Jan. 15 at 6:24 PM
$LEXX "Potential to develop and launch a patented DehydraTECH-CBD product within and/or outside of the diabetes/weight loss and hypertension marketplaces"
1 · Reply
Shubeedoo
Shubeedoo Jan. 15 at 5:45 PM
$LEXX Stock is at 70 cents. Anybody hear about any paid marketing plans? Needs it bad!
1 · Reply
Boston7452
Boston7452 Jan. 15 at 5:18 PM
$LEXX All share offer at 2 wouldnt be transformative. Also if they have their own or even a co-developed patented DHT-CBD "drug" then this becomes a billion dollar company. "our quest to deliver exciting and transformative returns to all Lexaria stakeholders!"
1 · Reply
hovian
hovian Jan. 15 at 5:10 PM
$LEXX will now an all share offer make sens at $2? Maybe SP is artificially down bcz an all share offer will b made and they will use average of 60 last days as reference? I hope some big foot buy this company...
0 · Reply
Boston7452
Boston7452 Jan. 15 at 5:04 PM
$LEXX This year the hope is a licensing deal but Im skeptical it'll happen this year based on CEO's letter. Outside of that management is supposed to release their plans for the year. That could reveal something.
0 · Reply
LongLEXX
LongLEXX Jan. 15 at 4:58 PM
$LEXX Let's play "Where's the Shares"
0 · Reply
TheRealStockRocket
TheRealStockRocket Jan. 15 at 4:51 PM
$LEXX $LEXX There is so much bs and lies posted here to try to get shareholders to sell so the scalpers and swingers can load again...dont be f-ing stupid....The dd I posted is the truth straight from the company filings...do your on dd. I just keep on accumulating here...on my way to 100K shares.
0 · Reply
PennyConnection1
PennyConnection1 Jan. 15 at 4:47 PM
$LEXX looking at the markets and seeing our 11% red
0 · Reply
hovian
hovian Jan. 15 at 4:41 PM
$LEXX oportunity?
0 · Reply
LongLEXX
LongLEXX Jan. 15 at 4:37 PM
$LEXX Not selling!!
1 · Reply
Makingmillions192
Makingmillions192 Jan. 15 at 4:11 PM
$LEXX They have 6-7 months after the notice to regain $1 with Nasdaq. Can’t wait to blow up the shorts here
0 · Reply
LongLEXX
LongLEXX Jan. 15 at 4:06 PM
$LEXX At this point any study we announce is likely not part of the MTA.
1 · Reply
TheRealStockRocket
TheRealStockRocket Jan. 15 at 4:04 PM
$LEXX 50k low volume walkdown....I got my net out for the manipulation and fake sellers.
0 · Reply
7_Angus_1
7_Angus_1 Jan. 15 at 3:56 PM
$LEXX "fully funded for 2026" does not mean no dilution risk this year. Without a partnership they will have to raise cash before year end... Likely mid year. Management will always want to have 6 to 12 months and operating cash available to them. So the timing of the MTA decision (April) to partner or not will determine dilution or not.
0 · Reply
Boston7452
Boston7452 Jan. 15 at 3:45 PM
$LEXX mgmt still needs to announce their plans for 2026.
1 · Reply
Shubeedoo
Shubeedoo Jan. 15 at 3:42 PM
$LEXX OK, we got news on the 1b. So what might be next that can create appreciation? Besides a buyout, what are we all waiting for?
0 · Reply
LongLEXX
LongLEXX Jan. 15 at 3:19 PM
$LEXX Or may very well not lead to an r/s!
2 · Reply
Taco_stocks
Taco_stocks Jan. 15 at 3:04 PM
$LEXX Just days away now from a delisting notice which may very well lead to a r/s this time
2 · Reply
Mralwaysgreen
Mralwaysgreen Jan. 15 at 2:51 PM
$LEXX volume is insanely low
0 · Reply